TRIANA Biomedicines

Discovery Tools (Healthcare) · Lexington, MA · Founded 2019 · Privately Held (backing)

Operator of a pharmaceutical company intended to discover and develop molecular glues. TRIANA Biomedicines is based in Lexington, MA and was founded in 2019. It was valued at $258 million at its later-stage round in Nov 2025, the last priced event on record. It has raised $246 million across 2 recorded rounds; the latest was a $120 million Series B in Nov 2025.

PMV mark · valuation
$258.0M
Oct 2026
Priced at
its later-stage round
Nov 2025
Total raised
$246.1M
Last round
Later Stage VC (Series B)
Nov 2025

Who backs TRIANA Biomedicines?

12 investors
InvestorType
Lightspeed Venture PartnersVenture capital
Bessemer Venture PartnersGrowth equity
RA Capital ManagementAsset manager
The Invus GroupPE / buyout
Pfizer VenturesOther
Logos CapitalHedge fund
Atlas VentureOther
Surveyor CapitalHedge fund
Ascenta CapitalVenture capital
Finchley Healthcare VenturesOther
+ 2 more investors · a free account shows the complete list
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

TRIANA Biomedicines investors

12 investors are on record for TRIANA Biomedicines, including Lightspeed Venture Partners, Bessemer Venture Partners, RA Capital Management and The Invus Group. The Series B in Nov 2025 drew 10 investors.

Free account
More of TRIANA Biomedicines with a free account
  • ·The complete investor list: 12 names
  • ·Everyone on the team, board and advisors included
  • ·Watch TRIANA Biomedicines: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 12 firms already write checks for companies like TRIANA Biomedicines in discovery tools (healthcare). Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View